Vir Biotechnology, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDVir Biotechnology, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings growth of 59% provides fundamental context to the price action. However, price is extended 30% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $7.90 | +15.13% | ABOVE |
| 50 SMA | $7.01 | +29.63% | ABOVE |
| 100 SMA | $6.49 | +40.07% | ABOVE |
| 150 SMA | $6.00 | +51.63% | ABOVE |
| 200 SMA | $5.80 | +56.78% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VIR in an uptrend right now?
VIR has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, VIR is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is VIR overbought or oversold?
VIR's RSI (14) is 66. The stock is in neutral territory, neither overbought nor oversold.
Is VIR outperforming the market?
VIR has a Relative Strength (RS) Rating of 92 out of 99. Yes, VIR is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is VIR in its 52-week range?
VIR is trading at $9.09, which is 83% of its 52-week high ($10.94) and 73% above its 52-week low ($4.16).
How volatile is VIR?
VIR has a Beta of 1.49 and 52-week volatility of 73%. It's more volatile than the S&P 500 - expect bigger swings.